Evolocumab reduces the relative risk of major adverse limb events (MALEs), which can lead to limb loss, in patients with stable atherosclerotic cardiovascular (CV) disease with or without peripheral artery disease (PAD), a subgroup analysis of the FOURIER trial has shown.
Researchers from Duke University in Durham, North Carolina, US, found that up to a third of patients discontinue proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor treatment due to inadequate insurance coverage.
An interatrial shunt device (IASD) has demonstrated significant reductions in pulmonary capillary wedge pressure (PCWP) at exercise and a good safety profile in patients with heart failure with preserved ejection fraction (HFpEF).
Treating high-risk patients with cardiovascular (CV) disease to LDL-cholesterol (LDL-C) goals of ≤70 mg/dL may not be feasible despite an influx of new LDL-C lowering drugs, according to Dr Jennifer Robinson of the University of Iowa College of Public Health in Iowa City, Iowa, US.
About half of patients with cardiovascular disease (CVD) may be eligible forproprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor therapy and results from a study of a large Canadian population-based cohort show such therapy may prevent CV events, though with significant costs.
New safety and efficacy data for two proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitors show that patients at high cardiovascular (CV) risk reach target LDL-cholesterol (LDL-C) levels safely on these therapies.
Shared decision support with the use of standardized decision aids improves decision quality and reduces implantation of left ventricular assist device as destination therapy (DT-LVAD) in patients with advanced heart failure.
Blood pressure (BP) readings appeared to be similar regardless of whether BP measurements were attended or unattended by staff, nor were CV outcomes different between the two techniques, according to a post hoc survey on participants following the SPRINT* trial.
There are no advantages to liberal use of red blood cell (RBC) transfusion over restrictive use in moderate to high-risk patients undergoing cardiac surgery, the multicentre randomized noninferiority TRICS-III* trial has shown.
Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.
Diabetes, hypertension, and older age are associated with lower hospital readmission in patients with gastroparesis, while higher length of stay (LOS), drug abuse, and marijuana use increase the 30-day readmission rate, a study has shown.